Onco Wiki - Drogas

Cisplatin

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDRUG-CISPLATIN
TipoFármaco
Aliaces
CDDPPlatinolAQ de platinolCis-DDPЦисплатин
Situaciónreviewed 2026-04-26 | pending_clinical_signoff
EnfermedadesDIS-ADRENOCORTICAL-CARCINOMA DIS-BURKITT DIS-CERVICAL DIS-CHOLANGIOCARCINOMA DIS-ESOPHAGEAL DIS-GASTRIC DIS-HNSCC DIS-LARYNGEAL DIS-MCL DIS-MESOTHELIOMA DIS-NPC DIS-NSCLC DIS-PENILE-SCC DIS-SCLC DIS-TESTICULAR-GCT DIS-UROTHELIAL DIS-VULVAR-VAGINAL-SCC
FuentesSRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025

Datos sobre drogas

ClaseAgente alquilante de platino (primera generación)
MecanismoSquare-planar platinum(II) coordination complex. After cellular uptake and aquation (Cl displaced by water in low-chloride intracellular environment), the activated species forms intra- and inter-strand DNA cross-links, predominantly 1,2-d(GpG) and 1,2-d(ApG) adducts. These adducts distort the DNA helix, blocking replication and transcription, and trigger apoptosis when not repaired. Resistance mechanisms include enhanced nucleotide excision repair, glutathione detoxification, and reduced cellular uptake (CTR1 transporter). Backbone for esophageal CRT, head-and-neck CRT, NSCLC, gastric (legacy), cervical, ovarian, testicular germ-cell, and bladder.
Dosificación típicaEsophageal definitive CRT (cisplatin/5-FU): cisplatin 75 mg/m² IV days 1, 29 + 5-FU 1000 mg/m²/d CIV days 1-4 and 29-32. Head-and-neck CRT: 100 mg/m² IV q21d × 3 cycles (high-dose) or 40 mg/m² weekly with RT. NSCLC (cisplatin/etoposide CRT): 50 mg/m² IV days 1, 8, 29, 36. NSCLC adjuvant (cisplatin/vinorelbine): 80 mg/m² IV day 1 q21d × 4. Testicular BEP: 20 mg/m² IV days 1-5 every 21 d × 3-4 cycles. Cervical CRT: 40 mg/m² IV weekly with RT (typically 5-6 cycles). Gastric (legacy ECF/EOX): 60-80 mg/m² IV q21d (FLOT preferred now). Mandatory hydration: ≥1-2 L NS pre-dose + 1-2 L post; mannitol diuresis or furosemide for high-dose schedules; Mg + K replacement.
Ucrania registradaCierto
NSZU reembolsadoCierto
Ucrania verificada por última vez2026-04-27

Advertencias

Notas

Mandatory hydration ≥3 L pre-dose + 24 h post; Mg / K pre-emptive supplementation. Consider carboplatin substitution for CrCl 50-60 or pre-existing hearing loss. Highly-emetogenic chemotherapy (HEC): ondansetron + dexamethasone + NK1-RA (aprepitant or fosaprepitant) + olanzapine premedication required (NCCN antiemesis v1.2025). Baseline + serial audiometry (esp. pediatric / younger adult patients). Uridine triacetate is NOT an antidote (FU only).

Utilizado por

Indicación

Esquema terapéutico